Search Within

Advanced Practice Providers

  1. "Lymphoma"
Formats
  1. Meeting Abstract (71)
  2. Journal Article (32)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (105)
  2. Department of Medicine (105)
  3. Hematologic Malignancies, Division of (105)
  4. Lymphoma (105)
  5. Nursing (76)
  6. Survivorship Research (70)

More Groups

People
  1. Maria Palomba (61)
  2. Alison Moskowitz (50)
  3. Andrew Zelenetz (48)
  4. Steven Horwitz (43)
  5. Ariela Noy (42)
  6. Paul Hamlin (38)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (10)
  4. 2022 (8)
  5. 2021 (19)
  6. 2020 (11)

More Years

Publications
  1. Blood (51)
  2. Hematological Oncology (9)
  3. Journal of Clinical Oncology (7)
  4. Biology of Blood and Marrow Transplantation (5)
  5. Blood Advances (4)
  6. Leukemia and Lymphoma (3)

More Publications

Publishers
  1. American Society of Hematology (55)
  2. Wiley Blackwell (10)
  3. American Society of Clinical Oncology (8)
  4. Elsevier Inc. (8)
  5. American Association for Cancer Research (4)
  6. Nature Publishing Group (4)

More Publishers

Results (105)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
    Journal Article

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K. V.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience
    Journal Article

    Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies
    Journal Article

    Lee, C. Y.; Shah, M. K.; Hoyos, D.; Solovyov, A.; Douglas, M.; Taur, Y.; Maslak, P.; Babady, N. E.; Greenbaum, B.; Kamboj, M.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax
    Meeting Abstract

    Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Timing and immune status after cellular therapies predict response to COVID-19 vaccines
    Meeting Abstract

    Tamari, R.; Politikos, I.; Knorr, D.; Vardhana, S.; Young, J.; Marcello, L.; Doddi, S.; Devlin, S. M.; Ramanathan, L.; Pessin, M. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save